• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Acceleron Pharma, Inc. - Product Pipeline Review - 2012 Product Image

Acceleron Pharma, Inc. - Product Pipeline Review - 2012

  • ID: 2194011
  • July 2012
  • 65 pages
  • Global Markets Direct

Acceleron Pharma, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Acceleron Pharma, Inc. - Product Pipeline Review - 2012” provides data on the Acceleron Pharma, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Acceleron Pharma, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Acceleron Pharma, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Acceleron Pharma, Inc. - Brief Acceleron Pharma, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Acceleron Pharma, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 5
Acceleron Pharma, Inc. Snapshot 6
Acceleron Pharma, Inc. Overview 6
Key Information 6
Key Facts 6
Acceleron Pharma, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
Acceleron Pharma, Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Acceleron Pharma, Inc. – Pipeline Products Glance 12
Acceleron Pharma, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Acceleron Pharma, Inc. – Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Acceleron Pharma, Inc. – Drug Profiles 15
ACE-031 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
ACE-041 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ACE-435 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ACE-536 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ACE-661 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ALKS693 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Sotatercept 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Acceleron Pharma, Inc. – Pipeline Analysis 25
Acceleron Pharma, Inc. – Pipeline Products by Therapeutic Class 25
Acceleron Pharma, Inc. – Pipeline Products By Target 27
Acceleron Pharma, Inc. – Pipeline Products by Route of Administration 28
Acceleron Pharma, Inc. – Pipeline Products By Mechanism of Action 29
Acceleron Pharma, Inc. – Recent Pipeline Updates 30
Acceleron Pharma, Inc. - Dormant Projects 32
Acceleron Pharma, Inc. – Locations And Subsidiaries 33
Head Office 33
Acceleron Pharma, Inc., Recent Developments 34
Acceleron Pharma, Inc.- Press Release 34
Apr 03, 2012: Acceleron’s ACE-041 Combined With VEGF Inhibitor Shows Potent Activity In Preclinical Model Of VEGF-Resistant Renal Cell Carcinoma 34
Dec 08, 2009: Acceleron Pharma Presents Findings Of ACE-536, A Novel Red Blood Cell-Forming Agent, At The 51st Annual Meeting Of The American Society Of Hematology 35
Dec 01, 2009: Acceleron Pharma To Present Clinical Trial Data Of ACE-536 At The 51st Annual Meeting Of The American Society of Hematology 35
Dec 01, 2009: Acceleron Pharma To Present Clinical Trial Results Of ACE-011 At The 51st Annual Meeting Of The American Society Of Hematology 36
Nov 04, 2009: Acceleron Pharma Initiates First-In-Human Study Of ACE-041, A Novel Angiogenesis Inhibitor, In Patients With Advanced Cancer 36
Sep 10, 2009: Acceleron Pharma’s ACE-031 Increases Lean Body Mass In Phase 1 Single Dose Clinical Trial 37
Jul 28, 2009: Acceleron and Celgene Initiate Phase II Study of ACE-011 to Treat Chemotherapy-Induced Anemia 37
Jun 10, 2009: Acceleron to Present ACE-031 Preclinical Study Results as Treatment for Loss of Muscle Mass and Function 38
Apr 14, 2009: Acceleron Pharma Presents Preclinical Study Results For ACE-041 At The AACR 100th Annual Meeting 2009 39
Jan 13, 2009: Acceleron Introduces Breakthrough Program For Treatment Of Anemia At The 27Th Annual Jp Morgan Healthcare Conference 39
Financial Deals Landscape 41
Acceleron Pharma, Inc., Deals Summary 41
Acceleron Pharma, Inc., Pharmaceuticals & Healthcare, Deal Details 43
Venture Financing 43
Acceleron Secures $30 Million In Series F Round Of Financing 43
Acceleron Pharma Secures $10.25 Million In Venture Financing 45
Acceleron Pharma Raises $8.4 Million In Venture Financing 46
Acceleron Pharma Secures $11 Million In Financing Round 47
Acceleron Pharma Secures $31 Million In Series C Financing 48
Acceleron Pharma Secures $30 Million In Series B Financing 51
Acceleron Pharma Secures $8 Million In Financing 53
Acceleron Pharma Secures $25 Million In Series A Financing 54
Partnerships 56
Acceleron Pharma Enters Into Co-Development Agreement With Celgene For ACE-536 56
Celgene Enters Into Co-Development Agreement With Acceleron Pharma 58
Artemis Pharma Enters Into Collaboration Agreement With Acceleron Pharma 60
Licensing Agreements 61
Shire Enters Into Licensing Agreement With Acceleron Pharma For ACE-031 61
Acceleron Pharma Enters Into Licensing Agreement With Alkermes 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables
Acceleron Pharma, Inc., Key Information 6
Acceleron Pharma, Inc., Key Facts 6
Acceleron Pharma, Inc. – Pipeline by Indication, 2012 9
Acceleron Pharma, Inc. – Pipeline by Stage of Development, 2012 10
Acceleron Pharma, Inc. – Monotherapy Products in Pipeline, 2012 11
Acceleron Pharma, Inc. – Phase II, 2012 12
Acceleron Pharma, Inc. – Phase I, 2012 13
Acceleron Pharma, Inc. – Pre-Clinical, 2012 14
Acceleron Pharma, Inc. – Pipeline By Therapeutic Class, 2012 26
Acceleron Pharma, Inc. - Pipeline By Target, 2012 27
Acceleron Pharma, Inc. – Pipeline By Route of Administration, 2012 28
Acceleron Pharma, Inc. – Pipeline Products By Mechanism of Action, 2012 29
Acceleron Pharma, Inc. – Recent Pipeline Updates, 2012 30
Acceleron Pharma, Inc. - Dormant Developmental Projects,2012 32
Acceleron Pharma, Inc., Deals Summary 41
Acceleron Secures $30 Million In Series F Round Of Financing 43
Acceleron Pharma Secures $10.25 Million In Venture Financing 45
Acceleron Pharma Raises $8.4 Million In Venture Financing 46
Acceleron Pharma Secures $11 Million In Financing Round 47
Acceleron Pharma Secures $31 Million In Series C Financing 48
Acceleron Pharma Secures $30 Million In Series B Financing 51
Acceleron Pharma Secures $8 Million In Financing 53
Acceleron Pharma Secures $25 Million In Series A Financing 54
Acceleron Pharma Enters Into Co-Development Agreement With Celgene For ACE-536 56
Celgene Enters Into Co-Development Agreement With Acceleron Pharma 58
Artemis Pharma Enters Into Collaboration Agreement With Acceleron Pharma 60
Shire Enters Into Licensing Agreement With Acceleron Pharma For ACE-031 61
Acceleron Pharma Enters Into Licensing Agreement With Alkermes 63

List of Figures
Acceleron Pharma, Inc. – Pipeline by Indication, 2012 8
Acceleron Pharma, Inc. – Pipeline by Stage of Development, 2012 10
Acceleron Pharma, Inc. – Monotherapy Products in Pipeline, 2012 11
Acceleron Pharma, Inc. – Pipeline By Therapeutic Class, 2012 25
Acceleron Pharma, Inc. - Pipeline By Target, 2012 27
Acceleron Pharma, Inc. - Pipeline Products By Mechanism of Action, 2012 29

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos